--- title: "A Look At Charles River Laboratories (CRL) Valuation As CEO Succession Plan Takes Shape" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/272381855.md" description: "Charles River Laboratories (CRL) is undergoing a leadership transition with CEO James C. Foster retiring in May 2026, succeeded by COO Birgit Girshick. The company has seen a strong share price performance, with a 30-day return of 13.36% and a 90-day return of 28.62%. However, it is considered overvalued at $218.82 compared to a fair value of $188.93. Analysts highlight risks related to non-animal methods and demand pressures, while also noting CRL's lower price-to-sales ratio compared to industry peers, suggesting potential market caution." datetime: "2026-01-13T08:35:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/272381855.md) - [en](https://longbridge.com/en/news/272381855.md) - [zh-HK](https://longbridge.com/zh-HK/news/272381855.md) --- > 支持的语言: [English](https://longbridge.com/en/news/272381855.md) | [繁體中文](https://longbridge.com/zh-HK/news/272381855.md) # A Look At Charles River Laboratories (CRL) Valuation As CEO Succession Plan Takes Shape Charles River Laboratories International (CRL) has announced a major leadership transition, with long-time CEO James C. Foster scheduled to retire in May 2026 and Chief Operating Officer Birgit Girshick named as his successor. See our latest analysis for Charles River Laboratories International. The CEO succession news comes after a strong period for the shares, with a 30 day share price return of 13.36% and a 90 day share price return of 28.62%. The 1 year total shareholder return of 15.08% compares with weaker 3 and 5 year total shareholder returns, which indicates that recent momentum has increased following leadership and M&A announcements. If you are looking beyond Charles River Laboratories International, this could be a good moment to scan other healthcare stocks that might fit your watchlist next. With the shares up strongly over the past 3 months, trading at $218.82 and sitting above an average analyst price target of $203.33, the key question now is whether CRL still trades at a discount or if the market is already pricing in future growth. ## Most Popular Narrative: 15.8% Overvalued The most followed narrative sees Charles River Laboratories International trading above its fair value estimate of $188.93 compared with the last close at $218.82, and ties that gap to a detailed earnings recovery story. > _Strategic focus on cost reduction (over $175M in annualized savings expected in 2025), disciplined capital allocation, and improved working capital management not only buttress current profitability but free up cash flow for continued investment in high-growth areas and M&A, strengthening long-term earnings and free cash flow generation._ _Read the complete narrative._ Want to see what kind of revenue path, margin rebuild, and future P/E multiple are being baked into that fair value line? The narrative leans on a specific mix of modest top line growth, a sharp swing into profitability and a valuation multiple that sits below many peers yet still assumes a meaningful rerating from today. The details behind those assumptions are where the real story sits. **Result: Fair Value of $188.93 (OVERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, there is still a real risk that faster adoption of non animal methods, or sustained pressure on Discovery and Safety Assessment demand, could derail that earnings rebuild story. Find out about the key risks to this Charles River Laboratories International narrative. ## Another View: Multiples Point to Value Support While the popular narrative frames Charles River Laboratories International as about 15.8% overvalued versus an intrinsic value of $188.93, the market’s own pricing tells a different story. On a P/S of 2.7x, CRL trades below the US Life Sciences industry average of 3.8x and well under a 7.7x peer average, with only a small gap to a fair ratio of 2.9x that our model suggests the market could move toward. That mix of discount to peers and only a modest premium to fair ratio raises a simple question for you: is the crowd too cautious about execution and growth, or are the narrative risks still underappreciated? See what the numbers say about this price — find out in our valuation breakdown. NYSE:CRL P/S Ratio as at Jan 2026 ## Build Your Own Charles River Laboratories International Narrative If you see the numbers differently, or simply prefer to test your own assumptions against the data, you can build a complete view in minutes: Do it your way. A great starting point for your Charles River Laboratories International research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. ## Looking for more investment ideas? If you stop with just one company, you could miss opportunities that fit your style much better, so take a few minutes to scan a wider set of ideas. - Target potential mispricings by checking out these 878 undervalued stocks based on cash flows that might offer a more attractive entry based on their cash flow profiles. - Ride powerful tech trends by reviewing these 26 AI penny stocks where artificial intelligence is a core part of the business model. - Boost your income focus by scanning these 12 dividend stocks with yields \> 3% that may suit a portfolio built around regular cash returns. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### 相关股票 - [Charles River Laboratorie (CRL.US)](https://longbridge.com/zh-CN/quote/CRL.US.md) ## 相关资讯与研究 - [Charles River Laboratories Stock: Is CRL Underperforming the Healthcare Sector?](https://longbridge.com/zh-CN/news/280226019.md) - [New York State Common Retirement Fund Reduces Position in Charles River Laboratories International, Inc. $CRL](https://longbridge.com/zh-CN/news/268594179.md) - [Tvardi Therapeutics Warns Animal Welfare Rules Could Raise Costs and Delay Drug Development](https://longbridge.com/zh-CN/news/281500356.md) - [Jacksonville Zoo and Botanical Gardens retains AZA accreditation for animal care excellence](https://longbridge.com/zh-CN/news/280919745.md) - [10:12 ETPet Supplies Plus and Wag N' Wash Reinforce Commitment to Local Communities, Expand Local Giving Initiatives](https://longbridge.com/zh-CN/news/281037434.md)